Tiziana Life Sciences LTD
15
3
4
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
40.0%
6 terminated/withdrawn out of 15 trials
25.0%
-61.5% vs industry average
0%
0 trials in Phase 3/4
100%
2 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab
Role: lead
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Role: lead
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
Role: lead
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
Role: collaborator
Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients
Role: lead
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Role: lead
Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers
Role: lead
Milciclib in Combination With Gemcitabine in Advanced NSCLC
Role: lead
A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease
Role: lead
In-patient COVID-19 Study of Intranasal Foralumab
Role: lead
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
Role: lead
Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma
Role: lead
Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
Role: lead
Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
Role: lead
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
Role: lead
All 15 trials loaded